New IMB16-4 Hot-Melt Extrusion Preparation Improved Oral Bioavailability and Enhanced Anti-Cholestatic Effect on Rats

References

• Hasegawa S, Yoneda M, Kurita Y, et al. Cholestatic liver disease: current treatment strategies and new therapeutic agents. Drugs. 2021;81(10):1181–1192. doi:10.1007/s40265-021-01545-7
   PubMed Web of Science ®Google Scholar
• Wagner M, Fickert P. Drug therapies for chronic cholestatic liver diseases. Annu Rev Pharmacol Toxicol. 2020;60:503–527. doi:10.1146/annurev-pharmtox-010818-021059
   PubMed Web of Science ®Google Scholar
• Phaw NA, Leighton J, Dyson JK, et al. Managing cognitive symptoms and fatigue in cholestatic liver disease. Expert Rev Gastroenterol Hepatol. 2021;15(3):235–241. doi:10.1080/17474124.2021.1844565
   PubMed Web of Science ®Google Scholar
• Qiu J, Yan J, Liu W, et al. Metabolomics analysis delineates the therapeutic effects of Huangqi decoction and astragalosides on α-naphthylisothiocyanate (ANIT) -induced cholestasis in rats. J Ethnopharmacol. 2021;268:113658. doi:10.1016/j.jep.2020.113658
   PubMed Web of Science ®Google Scholar
• De Vloo C, Nevens F. Cholestatic pruritus: an update. Acta Gastroenterol Belg. 2019;82(1):75–82.
   PubMed Web of Science ®Google Scholar
• Cazzagon N, Floreani A. Primary biliary cholangitis: treatment. Curr Opin Gastroenterol. 2021;37(2):99–104. doi:10.1097/MOG.0000000000000708
   PubMed Web of Science ®Google Scholar
• Chen L, Wei S, Liu H, et al. Paeoniflorin protects against ANIT-induced cholestatic liver injury in rats via the activation of SIRT1-FXR signaling pathway. Evid Based Complement Alternat Med. 2021;2021:8479868. doi:10.1155/2021/8479868
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Dyson JK, Alexander GJM, et al. The British society of gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568–1594. doi:10.1136/gutjnl-2017-315259
   PubMed Web of Science ®Google Scholar
• Chapman RW, Lynch KD. Obeticholic acid-a new therapy in PBC and NASH. Br Med Bull. 2020;133(1):95–104. doi:10.1093/bmb/ldaa006
   PubMed Web of Science ®Google Scholar
• Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet. 2020;396(10266):1915–1926. doi:10.1016/S0140-6736(20
   PubMed Web of Science ®Google Scholar
• Ge MX, Niu WX, Ren JF, et al. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters. Acta Pharmacol Sin. 2019;40(7):895–907. doi:10.1038/s41401-018-0195-3
   PubMed Web of Science ®Google Scholar
• Yang S, Wei L, Xia R, et al. Formononetin ameliorates cholestasis by regulating hepatic SIRT1 and PPARα. Biochem Biophys Res Commun. 2019;512(4):770–778. doi:10.1016/j.bbrc.2019.03.131
   PubMed Web of Science ®Google Scholar
• Ye X, Zhang T, Han H. PPARα: a potential therapeutic target of cholestasis. Front Pharmacol. 2022;13:916866. doi:10.3389/fphar.2022.916866
   PubMed Web of Science ®Google Scholar
• Gallucci GM, Trottier J, Hemme C, et al. Adjunct fenofibrate up-regulates bile acid glucuronidation and improves treatment response for patients with cholestasis. Hepatol Commun. 2021;5(12):2035–2051. doi:10.1002/hep4.1787
   PubMed Web of Science ®Google Scholar
• Xu S, Qiao X, Peng P, et al. Da-Chai-Hu-Tang protects from acute intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPARα. Front Pharmacol. 2022;13:847483. doi:10.3389/fphar.2022.847483
   PubMed Web of Science ®Google Scholar
• Gao L, Wang L, Woo E, et al. Clinical management of primary biliary cholangitis-strategies and evolving trends. Clin Rev Allergy Immunol. 2020;59(2):175–194. doi:10.1007/s12016-019-08772-7
   PubMed Web of Science ®Google Scholar
• Lu Z, Li S, Luo J, et al. Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate. Pharmazie. 2021;76(2):103–108. doi:10.1691/ph.2021.0988
   PubMed Web of Science ®Google Scholar
• Carrion AF, Lindor KD, Levy C. Safety of fibrates in cholestatic liver diseases. Liver Int. 2021;41(6):1335–1343. doi:10.1111/liv.14871
   PubMed Web of Science ®Google Scholar
• Niu X, Wang X, Niu B, et al. Novel IMB16-4 compound loaded into silica nanoparticles exhibits enhanced oral bioavailability and increased anti-liver fibrosis in vitro. Molecules. 2021;26(6):1545. doi:10.3390/molecules26061545
   PubMed Web of Science ®Google Scholar
• Niu X, Wang X, Niu B, et al. New IMB16-4 nanoparticles improved oral bioavailability and enhanced anti-hepatic fibrosis on rats. Pharmaceuticals. 2022;15(1):85. doi:10.3390/ph15010085
   Web of Science ®Google Scholar
• Niu X, Meng Y, Wang Y, et al. Established liposome-coated IMB16-4 polymeric nanoparticles (LNPs) for increasing cellular uptake and anti-fibrotic effects in vitro. Molecules. 2022;27(12):3738. doi:10.3390/molecules27123738
   PubMed Web of Science ®Google Scholar
• Simões MF, Pinto RMA, Simões S. Hot-Melt Extrusion: a roadmap for product development. AAPS PharmSciTech. 2021;22(5):184. doi:10.1208/s12249-021-02017-7
   PubMed Web of Science ®Google Scholar
• Zheng Y, Pokorski JK. Hot melt extrusion: an emerging manufacturing method for slow and sustained protein delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(5):e1712. doi:10.1002/wnan.1712
   PubMed Web of Science ®Google Scholar
• Kamata S, Oyama T, Saito K, et al. PPARα ligand-binding domain structures with endogenous fatty acids and fibrates. iScience. 2020;23(11):101727. doi:10.1016/j.isci.2020.101727
   PubMed Web of Science ®Google Scholar
• MacArthur Clark JA, Sun D. Guidelines for the ethical review of laboratory animal welfare People’s Republic of China National Standard GB/T 35892-2018. Animal Model Exp Med. 2020;3:103–113. doi:10.1002/ame2.12111
   PubMedGoogle Scholar
• Yao J, Yan J, Wu J, et al. Predicting target genes of San-Huang-Chai-Zhu formula in treating ANIT-induced acute intrahepatic cholestasis rat model via bioinformatics analysis combined with experimental validation. Evid Based Complement Alternat Med. 2021;2021:5320445. doi:10.1155/2021/5320445
   PubMed Web of Science ®Google Scholar
• Hua H, Dai M, Luo Y, et al. Basal PPARα inhibits bile acid metabolism adaptation in chronic cholestatic model induced by α-naphthylisothiocyanate. Toxicol Lett. 2019;300:31–39. doi:10.1016/j.toxlet.2018.10.015
   PubMed Web of Science ®Google Scholar
• You H, Ma X, Efe C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022;16(1):1–23. doi:10.1007/s12072-021-10276-6
   PubMed Web of Science ®Google Scholar
• Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2021 practice guidance update from the American association for the study of liver diseases. Hepatology. 2022;75(4):1012–1013. doi:10.1002/hep.32117
   PubMed Web of Science ®Google Scholar